公开(公告)号：US20160367655A1

公开(公告)日：2016-12-22

申请号：US15075279

申请日：2016-03-21

申请人： Sanofi Pasteur Limited ,  Sanofi Pasteur, S.A.

发明人： Scott Gallichan ,  Ausra Mancevski ,  Nathalie Reveneau ,  Jin Su ,  Francois Dalencon ,  Jean Haensler

IPC分类号： A61K39/118 ,  A61K39/39

CPC分类号： A61K39/39 ,  A61K9/0019 ,  A61K9/107 ,  A61K9/1075 ,  A61K39/118 ,  A61K47/44 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/572 ,  A61K2039/575

摘要： The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.

摘要翻译： 本发明提供了包含来自至少一种衣原体血清型和佐剂的衣原体主要外膜蛋白（本文称为“MOMP”）的组合物，其特征在于所述佐剂包含具有CAS号287180-63-6的产物E6020。 该组合物还可以包含至少一种载体体系（例如乳液，矿物颗粒）。 MOMP蛋白可以衍生自衣原体（例如沙眼衣原体，沙眼衣原体，肺炎衣原体，鹦鹉热鹦鹉或C.沙眼衣原体MoPn）的任何种类。 在优选的实施方案中，组合物包含一种或多种主要的外膜蛋白，其各自衍生自沙眼衣原体的不同血清型。 本发明还提供了通过向受试者施用本发明的组合物来诱导受试者对衣原体（例如沙眼衣原体）的免疫应答的方法。

公开(公告)号：US20130295164A1

公开(公告)日：2013-11-07

申请号：US13940398

申请日：2013-07-12

申请人： SANOFI PASTEUR S.A.

发明人： Jean Haensler ,  Bruno Guy

IPC分类号： A61K39/095

CPC分类号： A61K39/095 ,  A61K9/1272 ,  A61K9/1277 ,  A61K39/02 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/6068

摘要： The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof. The LPS may, for example, be the LOS of a non-enteric Gram-negative bacterium such as N. meningitidis.

摘要翻译： 本发明的主题是用于对革兰氏阴性细菌的LPS进行佐剂化的方法，根据该方法将LPS或LPS脂质体（脂质体中配制的LPS）与脂质化的人 - 转铁蛋白受体亚基B（TbpB蛋白）混合 脑膜炎奈瑟氏球菌或其脂质化片段或（ii）LPS和脑膜炎奈瑟氏球菌的脂化TbpB或其脂化片段一起配制在脂质体中; 或（iii）LPS与脑膜炎奈瑟球菌的脂质化TbpB或其脂质化片段缀合，以获得不含OMV的制剂，并且能够在给予哺乳动物之后诱导抗LPS免疫应答 通过与在其中省略了脑膜炎奈瑟球菌的脂质化TbpB或其脂化片段的相应制剂给药后观察到的抗LPS免疫应答相比，其得到改善; 以及其疫苗组合物。 LPS可以是例如非肠溶革兰氏阴性细菌如脑膜炎奈瑟氏球菌的LOS。